AstraZeneca Tries to Extend the Life of Acid Reflux Drug
Tuesday, June 1st, 2010Today AstraZeneca encountered a major setback in trying to extend the patent life of it blockbuster acid reflux drug Nexium. The patent was denied a patent extension by US regulators who did not see what the wanted when Astra tried to combine the drug with aspirin.
Loss of patent for Nexium and its 5 billion in yearly sales would be a big problem for AstraZeneca, who is trying to develop new drugs to fill the shoes of those who have lost patent protection in key markets.
According to ABC news,
The Anglo-Swedish drugmaker said it got a Complete Response Letter (CRL) from the U.S. Food and Drug Administration for its application to market Axanum, which combines aspirin with esomeprazole, the active ingredient in Nexium.
The delay for Axanum follows success with another Nexium line extension product, Vimovo, which won a green light from the FDA at the end of April. Vimovo, developed with Pozen, combines the anti-inflammatory drug naproxen and esomeprazole.
AstraZeneca faces another regulatory hurdle on Wednesday when an FDA expert panel meets to consider whether to approve its new infant lung drug motavizumab.
Winning over the panel may be tough, after FDA staff reported in briefing documents released last week that the drug carried a higher risk of causing severe allergic reactions than the company’s older product Synagis.
The loss of Nexium’s patent would definitely lower prices, as generic competition would not be far behind. One way or another, there is no reason sweat it’s approval, buy your drugs here at ePharmacies.com to save now!
Tweet

Heartburn drugs called proton pump inhibitors (PPIs) — such as 